Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription
Posted March 31, 2008
Cancer risk seen with J&J foot gel: FDA
Analysis of: Cancer risk seen with J&J foot gel: FDA | uk.reuters.com
Author: GLG Member Program Contributor
 "A Johnson & Johnson foot gel used by diabetics may increase the risk of cancer and death, U.S. health officials said on Thursday in announcing an investigation into the issue."
Posted March 31, 2008
Oxford BioMedica Report Encouraging New Phase II Trial Results With TroVax(R) in Prostate Cancer
Analysis of: Oxford BioMedica Report Encouraging New Phase II Trial Results With TroVax(R) in Prostate Cancer | www.pipelinereview.com
Author: GLG Member Program Contributor
Phase II results ++
Posted March 31, 2008
Immunoconjugates Are Better in Theory Than Practice
Analysis of: Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine Columbia University College of Physicians and Surgeons
Immunomedics has developed three new immunoconjugates between monoclonal antibodies and SN-38 i an effort to target colon, pancreas and lung cancer.  Preclinical data are effective in a metastatic colon cancer model but there are no clinical data.
Posted March 27, 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Analysis of: Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers | www.pipelinereview.com
Author: GLG Member Program Contributor
The article published in the www.pipelinereview.com is presenting the clinical efficacy of three new antibody-drug conjugates aimed at treating pancreatic, colon, and lung cancers. The chemical compunds of each of these drugs are designed to treat specific cancer without posing a threat to normal...
Posted March 27, 2008
Pronai Therapeutics, Inc. cleared to begin Phase I clinical trials for the first DNA interference (DNAi (R)) therapeutic
Analysis of: Pronai Therapeutics, Inc. cleared to begin Phase I clinical trials for the first DNA interference (DNAi (R)) therapeutic | www.pipelinereview.com
Author: GLG Member Program Contributor
DNAi technology, as presented by Pronal Therapeutics provides an exciting opportunity to use this technology as a therapeutic.  PNT2258 may be an important nucleic acid in combating certain types of cancer and solid tumor.  It is an important milestone to have FDA acceptance to begin Phase...
Posted March 27, 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Analysis of: Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers | www.pipelinereview.com
Author: GLG Member Program Contributor
The use of immunoconjugates in the development of monoclonal antibodies has been long tested with toxins but not with pro-drugs
Posted March 27, 2008
Cigarette Company Paid for Lung Cancer Study
Analysis of: Cigarette Company Paid for Lung Cancer Study | www.nytimes.com
Author: GLG Member Program Contributor
Support from a cigarette manufacturer raises questions as to the conclusions from this study which says early detection by repetitive CT's can improve cancer cure rates by early detection. (making smoking safer?)
Posted March 25, 2008
Prostate-Cancer Treatment Questioned
Analysis of: Prostate-Cancer Treatment Questioned | online.wsj.com
Author: GLG Member Program Contributor
Hormone blocking therapy is added to radiation, unnecessarily, in early prostate cancer patients. The result in early stage patients is unnecessary side effects and reduced quality of life. Go figure.
Posted March 25, 2008
Vermillion Announces Positive Results From Clinical Trial of Ovarian Tumor Triage Test; Study Meets Primary Endpoints
Analysis of: Vermillion Announces Positive Results From Clinical Trial of Ovarian Tumor Triage Test; Study Meets Primary Endpoints | www.pipelinereview.com
Author: GLG Member Program Contributor
Early detection of ovarian cancer is of paramount importance
Posted March 24, 2008
Researchers Find Cause of Severe Allergic Reaction to Cancer Drug
Analysis of: Researchers Find Cause of Severe Allergic Reaction to Cancer Drug | pharmalive.com
Author: GLG Member Program Contributor
Antibodies have been identified that explain allergic reactions that can terminate it's use in individuals who "react."
Previous Page : 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Next131 to 140 of 718

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-28T21:45:18.233